Hoffmann-la Roche Inc.

Other

Genentech, Inc.

F. Hoffmann-la Roche Ag

Nancy-Ellen Haynes

Ramakanth Sarabu

Robert Francis Kester

Wendy Lea Corbett

Paige Erin Mahaney

Nathan Robert Scott

Jefferson Wright Tilley

Yimin Qian

Kshitij Chhabilbhai Thakkar

Joseph Samuel Grimsby

Fred Thomas Bizzarro

George W Holland

Kevin Richard Guertin

Joseph Francis Grippo

Sung-Sau So

Sherrie Lynn Pietranico-Cole

Steven Joseph Berthel

Lida Qi

Paul Gillespie

Denis John Kertesz

Robert Alan Goodnow, Jr

Nader Fotouhi

Eric Mertz

Adrian Wai-Hing Cheung

Lee Apostle McDermott

Stuart Hayden

Joseph Anthony Bilotta

Jagdish Kumar Racha

Michael Paul Myers

Ka Wang

Li Chen

Matthew Michael Hamilton

Alexander Mayweg

Lichun Feng

Fariborz Firooznia

Steven Gregory Mischke

Mark Edward Zak

Shaoqing Chen

Johannes Cornelius Hermann

Kyungjin Kim

Jenny Tan

Agnieszka Kowalczyk

Francis A Mennona

Pamela Loreen Rossman

Qiang Zhang

Lin Yi

John A Brinkman

Kevin W Anderson

Nicholas Marcopulos

Bruce Lester Banner

Antonio Focella

Christine M Lukacs-Lesburg

Alexander V Mayweg

Robert Alan Goodnow Jr

Kevin William DrANDERSON

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as obesity, hyperlipidemia, hypercholesterolemia and diabetes and other related disorders and diseases, and may be useful for other diseases such as NASH, atherosclerosis, cardiovascular diseases, hypothyroidism, thyroid cancer and other disorders and diseases related thereto.

Thyroid hormone analogs

There are provided compounds of the formula (I) wherein Q, Rand Rare defined herein. The compounds have activity as anticancer agents.

Pyrrolopyrimidone and pyrrolopyridone inhibitors of tankyrase

The invention relates to JNK inhibitors and corresponding methods, formulations, and compositions for inhibiting JNK and treating JNK-mediated disorders. The application discloses JNK inhibitors, as described below in Formula I: wherein the variables are as defined herein. The compounds and compositions disclosed herein are useful to modulate the activity of JNK and treat diseases associated with JNK activity. Disclosed are methods and formulations for inhibiting JNK and treating JNK-mediated disorders, and the like, with the compounds, and processes for making said compounds, and corresponding compositions, disclosed herein.

Aminomethyl quinolone compounds

Adamantyl compounds

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of metabolic diseases and disorders such as, for example, type II diabetes mellitus.

Pyridazinone glucokinase activators

Azaindole glucokinase activators

Provided herein are compounds of the formula (I):  as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as obesity, hyperlipidemia, hypercholesterolemia and diabetes and other related disorders and diseases, and may be useful for other diseases such as NASH, atherosclerosis, cardiovascular diseases, hypothyroidism, thyroid cancer and other disorders and diseases related thereto.

Prodrugs of thyroid hormone analogs

Pyrrolidinone glucokinase activators

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, type II diabetes mellitus and metabolic syndrome.

Adamantyl-pyrazole carboxamides as inhibitors of 11&#x3b2;-hdroxysteroid dehydrogenase

Pyrazolones as inhibitors of 11&#x3b2;-hydroxysteroid dehydrogenase

2,3-Di-substituted N-heteroaromatic propionamides with said substitution at the 2-position being a substituted phenyl group and at the 3-position being a polar ring, said propionamides being glucokinase activators which increase insulin secretion in the treatment of type II diabetes.

Substituted-cycloalkyl and oxygenated-cycloalkyl glucokinase activators

2,3-Di-substituted N-heteroaromatic propionamides with said substitution at the 3-position being a substituted phenyl group and at the 2-position being a methyl cycloalkyl ring, said propionamides being glucokinase activators which increase insulin secretion in the treatment of type II diabetes.

Heteroaromatic glucokinase activators

The present invention provides a compound according to formula I where the substituent designations are provided in the specification. Pharmaceutical compositions comprising a compound according to formula I are also provided.

5-substituted-six-membered heteroaromatic glucokinase activators

Growing community of inventors

Cranford, NJ, United States of America

Nancy-Ellen Haynes